DexCom Inc, joins with the life sciences team of Google to develop a series of smaller and inexpensive next-generation CGM products for diabetes care.
New products will incorporate Google's miniaturized electronics platform with DexCom's best-in-class sensor technology. This will improve the outcomes by CGM products and will reduce the costs for diabetes care.
"This partnership has the potential to change the face of diabetes technology forever. Working together, we believe we can introduce products that will move us beyond our core Type 1 business to become the standard of care for all people living with diabetes," said Kevin Sayer, President and Chief Executive Officer of DexCom.
"We're committed to developing new technologies that will help move health care from reactive to proactive. This collaboration is another step towards expanding monitoring options and making it easier for people with diabetes to proactively manage their health," said Andrew Conrad, head of the life sciences team at Google.
"Five plus years from now, our goal would be to have a sensor that would be something that's miniaturized, that looks more like a bandage than a medical device, that's fully disposable. You get it to the point where you overcome basically all of the objections that a patient would have to wearing the device - it talks to your phone, it doesn't have to be calibrated, you don't take fingersticks anymore - there really isn't a reason that you couldn't get very significant penetration into the Type 1 market in the US," he added.
Sayer said on the call that they expect the first product developed under the collaboration to launch in the next two to three years, with another generation in the next five years.